# Combined JAK inhibition and PD-1 immunotherapy for non–small cell lung cancer patients

*PRI Rank #10 · Topics and Trends in Most Cited Immunotherapy and Immune Responses Papers, Class of 2026*

*Canonical URL: https://pri.pepkio.com/top-papers/immunotherapy-and-immune-responses/2026/rank-10*

| Field | Value |
| --- | --- |
| Rank | #10 |
| 18m citations | 143 |
| Journal | Science |
| Year | 2024 |
| DOI | 10.1126/science.adf1329 |
| Corresponding authors | Divij Mathew, Melina E. Marmarelis, E. John Wherry, Andy J. Minn |
| Institution | University of Pennsylvania, United States |

**Ranking page:** [Topics and Trends in Most Cited Immunotherapy and Immune Responses Papers, Class of 2026](https://pri.pepkio.com/top-papers/immunotherapy-and-immune-responses/2026)

**Paper link:** [10.1126/science.adf1329](https://doi.org/10.1126/science.adf1329)

## Topics

JAK1 inhibition · itacitinib · PD-1 inhibition · Type I interferon (IFN-I) · Chronic inflammation · immunosuppression · Non-small cell lung cancer · Phase II clinical trial · CD8 T cell plasticity · T cell exhaustion · effector memory-like T cells · T cell clonotypes · terminal differentiation · combination immunotherapy · antitumor immune response · mouse tumor model · progressive disease · immune checkpoint blockade resistance · cytokine-driven immune dysfunction · T cell differentiation dynamics

## Cite this ranking

```
Pepkio Research Index (PRI). Topics and Trends in Most Cited Immunotherapy and Immune Responses Papers, Class of 2026. https://pri.pepkio.com/top-papers/immunotherapy-and-immune-responses/2026. Accessed 2026-07-21.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459
```